Jill Meynen

Ms. Jill Meynen

Medicine and life sciences, Hasselt University, Hasselt, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Jill MeynenJill Meynen
Jill Meynen
PAPeter Adriaensens
Peter Adriaensens
CMCriel Maarten
Criel Maarten
ELEvelyne Louis
Evelyne Louis
VKVanhove Karolien
Vanhove Karolien
EDElien Derveaux
Elien Derveaux
Lung cancer is the leading cause of cancer-related mortality worldwide. In order to improve its overall survival, early diagnosis is required. Since current screening methods still face some pitfalls, such as high false positive rates for low-dose computed tomography, researchers are still looking for early biomarkers to complement existing screening techniques in order to provide a safe, faster, and more accurate diagnosis. Biomarkers are biological molecules found in body fluids, such as plasma, that can be used to diagnose a condition or disease. Metabolomics has already been shown to be a powerful tool in the search for cancer biomarkers since cancer cells are characterized by impaired metabolism, resulting in an adapted plasma metabolite profile. The metabolite profile can be determined using nuclear magnetic resonance, or NMR. Although metabolomics and NMR metabolite profiling of blood plasma are still under investigation, there is already evidence for its potential for early-stage lung cancer diagnosis, therapy response, and follow-up monitoring. This review highlights some key breakthroughs in this research field, where the most significant biomarkers will be discussed in relation to their metabolic pathways and in light of the altered cancer metabolism.

25 March 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
Jill MeynenJill Meynen
Jill Meynen
PAPeter Adriaensens
Peter Adriaensens
CMCriel Maarten
Criel Maarten
ELEvelyne Louis
Evelyne Louis
VKVanhove Karolien
Vanhove Karolien
EDElien Derveaux
Elien Derveaux
Lung cancer is the leading cause of cancer related mortality worldwide. In order to improve its overall survival, early diagnosis is required. Since current screening methods still face some pitfalls, such as high false positive rates for low-dose computed tomography, researchers are still looking for early biomarkers to complement existing screening techniques in order to provide a safe, faster and more accurate diagnosis. Biomarkers are biological molecules found in body fluids, such as plasma, that can be used to diagnose a condition or disease. Metabolomics has already shown to be a powerful tool in the search for cancer biomarkers since cancer cells are characterised by impaired metabolism, resulting in an adapted plasma metabolite profile. The metabolite profile can be determined using nuclear magnetic resonance, or NMR. Although metabolomics and NMR metabolite profiling of blood plasma are still under investigation, there is already evidence for its potential for early-stage lung cancer diagnosis, therapy response, and follow-up monitoring. This review highlights some key breakthroughs in this research field, where the most significant biomarkers will be discussed in relation with their metabolic pathways and in light of the altered cancer metabolism.

19 March 2026
Verified
Conference Paper
Closed access
Jill MeynenJill Meynen
Jill Meynen
PAPeter Adriaensens
Peter Adriaensens
LMLiesbet Mesotten
Liesbet Mesotten
MTMichiel Thomeer
Michiel Thomeer
MCMaarten Criel
Maarten Criel
EDElien Derveaux
Elien Derveaux
Lung cancer is the most prevalent form of cancer worldwide and the leading cause of cancer-related mortality. The high mortality rate associated with this condition is primarily attributable to delayed diagnosis caused by the absence of symptoms in the early stages of the disease. To improve overall survival, early disease detection is of great importance. As current screening techniques for high-risk individuals face multiple challenges, this study aims to discover plasma-based metabolic biomarkers for improved early-stage non-small cell lung cancer (NSCLC) diagnosis. A prospective clinical study was conducted on 97 patients with resectable stage I-IIIA NSCLC. Fasted plasma samples were collected at six time points, including two preoperative and four postoperative, and analyzed using proton nuclear magnetic resonance (1H-NMR). Plasma metabolites were compared between pre- and postoperative conditions of 84 patients who met eligibility criteria using orthogonal partial least squares discriminant analysis (OPLS-DA). As patients who showed disease recurrence within 24 months were excluded from model training, preoperative samples represent early-stage NSCLC samples, while the postoperative samples represent healthy samples. The multivariate analysis showed a clear discrimination between the pre- (lung cancer) and postoperative (healthy) metabolite profiles of the patients, with sensitivity, specificity, and accuracy values of at least 90%, 89%, and 89%, respectively. Subsequent variable importance of projection (VIP) analysis identified lactate, asparagine, acetate, and cysteine significantly as the primary contributing metabolites, marking them as potential plasma biomarkers for early-stage NSCLC detection.